Needham Maintains Buy on Conmed, Lowers Price Target to $106
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on Conmed (NYSE:CNMD) but lowers the price target from $107 to $106.

July 25, 2024 | 9:46 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Mike Matson maintains a Buy rating on Conmed but lowers the price target from $107 to $106.
The Buy rating suggests continued confidence in Conmed's performance, but the slight reduction in the price target indicates a minor adjustment in expectations. This is likely to have a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100